CXCR4 was highly expressed in the bone destruction area of metastatic NSCLC samples. Also, it was related to poor survival in NSCLC patients with bone metastasis, with an increase in VCAM1 and a decrease in ADAM17. This evidence concerns the gene ADAM17 and bone metastasis.